Prostate Cancer Clinical Trials in Tennessee

Showing 321-340 of 360 trials

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

NCT00314782

Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer (HRPC)

Prostate Cancer

AstraZeneca44 participantsStarted Mar 2006

Buffalo, New York, United States • Greenville, South Carolina, United States • Nashville, Tennessee, United States +6 more locations

COMPLETEDPhase 329 miles

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

NCT00002723

Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of suramin is more effective for prostate cancer.

Prostate Cancer

National Cancer Institute (NCI)390 participantsStarted Jan 1996

Chicago, Illinois, United States • Chicago, Illinois, United States • Urbana, Illinois, United States +24 more locations

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Prostate Cancer Trials in Other Cities

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Family Quality of Life Among Families With a Member Who is a Cancer Patient

ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

3-AP in Treating Patients With Advanced Prostate Cancer

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Other Conditions in Tennessee